Description
Uses of Medication:
Havrix 720 Vaccine is indicated for active immunization against disease caused by hepatitis A virus (HAV). This drug is approved for use in patients one year of age and older. The primary immunization should be recommended at least 14 days prior to the expected exposure to HAV.
Dosage of Havrix 720 Vaccine:
Havrix 720 Vaccine should be administered by intramuscular injection only. It should not be given in the gluteal region; such injections can be responsible for causing suboptimal response. Do not administer this vaccine intravenously, intradermally, or subcutaneously.
The primary immunization for the adult patients consists of a single 1-mL dose and a 1-mL booster dose should be administered anytime between 6 & 12 months later. In adult patients, the injection should be recommended in the deltoid region.
The primary immunization for those patients who are children and adolescents (1 year through 1.5 years of age) consists of a single 0.5-mL dose and a 0.5-mL booster dose administered anytime between 6 & 12 months later. If a scheduled dose is missed or an event of excess dose occurs , interact with your healthcare provider and arrange another visit immediately.
Treatment Reactions: The mild side effects of Havrix include:
- redness
- swelling
- a hard lump
- soreness
- bruising or itching around the injection site
- feeling generally unwell
- fever
- headache
- loss of appetite
- feeling sick (nausea)
- vomiting
- tiredness
- diarrhoea
Warning & Precautions
- The tip caps of the prefilled syringes contain the natural rubber latex which can be responsible for causing the allergic reactions.
- Vaccine recipients and guardians should be informed about the potential benefits and risks of immunization with the Havrix.
- Emphasize, when educating vaccine recipients and guardians regarding potential side effects, that Havrix may contain non-infectious killed viruses and cannot cause hepatitis A infection.
- Vaccine recipients and guardians should be instructed in order to report any adverse events to their doctor.
- Safety as well as effectiveness of the Havrix have not been established in subjects younger than one year of age.
- Caution must be exercised when this vaccine is administered to a nursing woman.
- This hepatitis A vaccine should be recommended to a pregnant woman only if clearly required.
- Fainting may appear in association with the administration of the injectable vaccines, including Havrix.
